Dexlansoprazole injection - Jiangsu Aosaikang Pharmaceutical

Drug Profile

Dexlansoprazole injection - Jiangsu Aosaikang Pharmaceutical

Latest Information Update: 14 Jan 2017

Price : $50

At a glance

  • Originator Jiangsu Aosaikang Pharmaceutical
  • Class 2 pyridinylmethylsulfinylbenzimidazoles; Pyridines; Small molecules; Sulfoxides
  • Mechanism of Action Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Erosive oesophagitis; Gastro-oesophageal reflux

Most Recent Events

  • 01 Jan 2017 Jiangsu Aosaikang Pharmaceutical plans a phase I trial in Healthy volunteers in China (NCT03011125)
  • 01 Dec 2016 Preclinical trials in Erosive oesophagitis in China (IV)
  • 01 Dec 2016 Preclinical trials in Gastro-oesophageal reflux in China (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top